Gastrointestinal Motility in Patients With Neuroendocrine Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00789841|
Recruitment Status : Completed
First Posted : November 13, 2008
Last Update Posted : October 26, 2010
We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects. For this we will use radio-opaque markers and the newly developed Motility Tracking System (MTS).
Hypothesis: Patients with NET and carcinoid syndrome have decreased GITT, gastric emptying and small bowel transit time and an increase in phase III MMC activity compared to healthy subjects. Treatment with somatostatin analogues increase transit times and decrease phase III MMC activity and improves the clinical symptoms.
|Condition or disease||Intervention/treatment|
|Neuroendocrine Tumor||Device: Magnetic Tracking System (MTS) and radio-opaque markers|
|Study Type :||Observational|
|Actual Enrollment :||13 participants|
|Official Title:||Gastrointestinal Motility in Patients With Neuroendocrine Tumors-Effects of Sandostatin LAR|
|Study Start Date :||September 2008|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
|Patients with NET and diarrhea.||
Device: Magnetic Tracking System (MTS) and radio-opaque markers
MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
- Gastrointestinal transit time in NET patients [ Time Frame: End of the study ]
- Gastric emptying in NET patients [ Time Frame: End of the study ]
- Small intestinal transit time [ Time Frame: End of the study ]
- Small intestinal velocity [ Time Frame: End of the study ]
- Changes in carcinoid symptoms and biomarkers [ Time Frame: End of the study ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00789841
|Analfysiologisk afsnit, Aarhus University Hospital, Tage Hansensgade, entrance 11A|
|Aarhus, Denmark, 8000|